Janice Rose
Breast Cancer Care(GB)The Patients Association(GB)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Radiomics and Machine Learning in Medical Imaging, Global Cancer Incidence and Screening, MRI in cancer diagnosis, Advanced Breast Cancer Therapies
Most-Cited Works
- → The potential utility of abbreviated breast MRI (FAST MRI) as a tool for breast cancer screening: a systematic review and meta-analysis(2020)59 cited
- → Evaluation of an AI Model to Assess Future Breast Cancer Risk(2023)44 cited
- → Evaluating the effectiveness of abbreviated breast MRI (abMRI) interpretation training for mammogram readers: a multi-centre study assessing diagnostic performance, using an enriched dataset(2022)16 cited
- → ATNEC: A multicenter, randomized trial investigating whether axillary treatment can be avoided in patients with T1-3N1M0 breast cancer with no residual cancer in the lymph glands after neoadjuvant chemotherapy.(2022)11 cited
- → Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy (ATNEC).(2021)4 cited
- → Abstract OT1-04-01: ATNEC: A multi-centre, randomised trial investigating whether axillary treatment can be avoided in T1-3N1M0 breast cancer patients with no residual cancer in the lymph glands after neoadjuvant chemotherapy (clinicaltrials.gov: nct04109079)(2022)4 cited
- → Abstract OT-04-01: Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy - ATNEC (ClinicalTrials.gov NCT04109079)(2021)1 cited
- → Optimising the diagnostic accuracy of First post-contrAst SubtracTed breast MRI (FAST MRI) through interpretation-training: a multicentre e-learning study, mapping the learning curve of NHS Breast Screening Programme (NHSBSP) mammogram readers using an enriched dataset(2024)1 cited
- → Practice patterns in ongoing neoadjuvant ATNEC trial for patients with cT1-3N1M0 breast cancer: Response to neoadjuvant chemotherapy (NACT), targeted axillary dissection and breast conservation rates.(2023)